QPPV.COM KNOWLEDGE ASSESSMENT

Stapokibart: Classification, Mechanism, Clinical Evidence and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Stapokibart: Classification, Mechanism, Clinical Evidence and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should high response proportions reported at week 52 not automatically be interpreted as a controlled long-term treatment effect?

The week-52 results came from a follow-up that included open-label treatment and lacked a concurrent placebo comparator throughout EASI outcomes cannot be used beyond 16 weeks Long-term outcomes are valid only if every participant has the same baseline itch score Open-label studies cannot provide any useful safety or efficacy information

Question 2 of 10 Which governance action best supports ongoing pharmacovigilance for stapokibart?

Reconcile relevant literature, trial and spontaneous-report sources under applicable local requirements, and keep current local safety information under review Use the original NMPA notice as the only source indefinitely Replace local product information with a class-wide label summary Review only spontaneous reports because published evidence is not relevant to safety

Question 3 of 10 A colleague describes stapokibart as an anti-IL-4 ligand antibody. What is the most accurate correction?

It is an antibody directed against IL-4Rα, not against the IL-4 ligand It binds only IL-13 and has no effect on IL-4 signalling It is a topical anti-inflammatory medicine that reduces cytokine production in the skin It binds IL-4Rα only after IL-4 has already activated the receptor

Question 4 of 10 Which description best explains how stapokibart can interfere with signalling by both IL-4 and IL-13?

It neutralises circulating IL-4 and IL-13 ligands directly It binds IL-4Rα, a receptor component used in signalling pathways for both cytokines It blocks IL-13Rα1, the only receptor component shared by the two pathways It suppresses all type 2 immune activity by eliminating the relevant immune cells

Question 5 of 10 Which interpretation of stapokibart’s intended biological effect is most appropriate?

It completely abolishes type 2 immunity in every treated patient It attenuates IL-4Rα-dependent signalling, while leaving room for other disease mechanisms and variable clinical response It permanently corrects epidermal barrier dysfunction after one dose It acts only on itch and has no relationship to inflammatory signalling

Question 6 of 10 When reviewing aggregate safety findings from randomised induction, an open-label extension and real-world reports, what is the best approach?

Combine all reports without regard to source because they concern the same medicine Separate the evidence by source and study design, considering exposure and follow-up duration Use only the open-label extension because it has the longest follow-up Use spontaneous reports to calculate a controlled incidence rate

Question 7 of 10 A patient shows little improvement in atopic dermatitis despite treatment. Which statement best reflects the article’s pharmacovigilance guidance?

Lack of response can be clinically relevant even when it is not classified as an adverse reaction Lack of response should never be documented in pharmacovigilance records Lack of response proves that the patient experienced an adverse drug reaction Lack of response should be recorded only as a biomarker abnormality

Question 8 of 10 Which feature of the phase 3 study most directly supports a controlled comparison of stapokibart with placebo during induction?

The study was randomised, double-blind and placebo-controlled during the 16-week induction period All participants received open-label stapokibart throughout the full 52 weeks The study compared participants from different countries without a control group The extension period maintained a concurrent placebo comparator for every participant

Question 9 of 10 A patient’s dermatitis worsens after treatment begins, and the patient has a history of skin infections and prior immunosuppressive therapy. How should these details inform the case review?

They provide relevant clinical context that should be documented alongside the event and exposure timeline They establish that the worsening is unrelated to stapokibart They establish that the worsening is caused by stapokibart They are irrelevant once a suspected adverse event has been reported

Question 10 of 10 A medical-information response needs to state stapokibart’s dosing and pregnancy advice. Which approach is most appropriate?

Use the dosing and pregnancy wording from another IL-4Rα antibody because the target is shared Infer the advice from the phase 3 efficacy results Verify the current Chinese product label for the relevant details and use applicable local information Omit verification because the NMPA notice provides a complete product label

QPPV.com

Stapokibart: Classification, Mechanism, Clinical Evidence and Pharmacovigilance — Knowledge Assessment

Cookie Settings